Literature DB >> 4044023

Inhibition of association vs. dissociation of high-avidity DNA/anti-DNA complexes:possible involvement of secondary hydrogen bonds.

C J van Oss, R J Smeenk, L A Aarden.   

Abstract

Recent results on the conditions of ionic strength needed to prevent the association of dsDNA with high avidity human anti-dsDNA, were compared with the insufficiency of even the highest practicable ionic strengths to effect the dissociation of such antigen-antibody complexes, once formed (1). Further analysis of these results make us conclude that such high avidity dsDNA-anti-dsDNA complexes, which in the initial stages of their formation are mainly of the Coulombic variety, subsequently evolve, at least in part, into hydrogen bonds.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4044023     DOI: 10.3109/08820138509076148

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  4 in total

Review 1.  A comparison of assays used for the detection of antibodies to DNA.

Authors:  R Smeenk; K Brinkman; H van den Brink; T Swaak
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

Review 2.  Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease.

Authors:  R Smeenk; K Brinkman; H van den Brink; R M Termaat; J Berden; H Nossent; T Swaak
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

3.  The interaction of anti-DNA antibodies with DNA antigen: Evidence for hysteresis for high avidity binding.

Authors:  David S Pisetsky; Robert Shaffer; Dustin D Armstrong; Diane M Spencer
Journal:  Clin Immunol       Date:  2021-09-04       Impact factor: 10.190

4.  Murine monoclonal antibodies to DNA. A comparison of MRL/lpr NZB/W and chronically graft-versus-host-diseased mice.

Authors:  K Brinkman; A van Dam; H van den Brink; R M Termaat; J Berden; R Smeenk
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.